The injectable therapy setmelanotide, being developed by Rhythm Pharmaceuticals for Prader-Willi syndrome (PWS), curbs hyperphagia, or uncontrollable hunger, and reduces body weight in children and adults with obesity due to PWS. Those are the early findings of an exploratory Phase 2 clinical trial, ongoing at a single U.S.